QUEST DIAGNOSTICS INC(DGX)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Rank #381 of 2,879 stocksTOP 25%
Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.
Revenue Growth
Profitability
Balance Sheet
Earnings Quality
Free Cash Flow
Institutional Flow
Revenue Scale
Dilution Risk
DGX Stock Analysis & AI Quality Score
AI stock analysis and institutional research for QUEST DIAGNOSTICS INC (DGX), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores DGX at 69.1/100 on a 32-signal composite quality model, placing it at rank #381 of 2,879 stocks — the top 25% of the AI-ranked universe. DGX scores in the top quartile across revenue scale (87.4), balance sheet strength (75.7). Based on the latest XBRL financial filings (Q1 2026), QUEST DIAGNOSTICS INC reports quarterly revenue of $2.9B, net income of $252.0M, an operating margin of 13.8%. Top institutional holders of DGX by reported 13-F value include BlackRock,, VANGUARD CAPITAL MANAGEMENT, VANGUARD PORTFOLIO MANAGEMENT, based on the most recent SEC filings. DGX trades on the NYSE exchange and files with the SEC under CIK 1022079. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate DGX daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for QUEST DIAGNOSTICS INC directly from SEC EDGAR. QUEST DIAGNOSTICS INC's 13F Pro composite quality score has ranged between 8 and 79 since 2021, currently 69.1 — a declining long-term trajectory across 56 quarterly and live scoring snapshots.
What's Driving DGX's Business? Latest 10-Q Breakdown
✓ 18/18 datapoints verifiedAI-extracted from QUEST DIAGNOSTICS INC's 10-Q filed 2026-04-22 — Q1 2026 (quarter ended March 31, 2026). Every figure is machine-verified against the filing text on SEC EDGAR.
Quest Diagnostics Q1 2026 net revenue reached $2.895B (+9.2% YoY) driven by 10.9% volume growth; DIS organic growth of 9.2% offset by -1.3% revenue per requisition decline from Corewell/Fresenius mix.
Biggest Revenue Drivers
Total revenue: $2,895M+9.2% YoY
Organic growth of 9.2% driven by 10.8% organic volume growth (including ~7% from Corewell Health and Fresenius Medical Care relationships), partially offset by -1.3% revenue per requisition decline due to routine test business mix.
Risk assessment services and healthcare information technology businesses principally consistent with prior year.
Largest Expense Items
Increase primarily driven by higher compensation costs and supplies expense, partially offset by cost savings and productivity improvements from Invigorate program.
Increase primarily driven by higher compensation costs.
Principally consistent with prior year period.
Margins: Operating margin improved to 13.8% from 13.0% YoY, driven by organic revenue growth of 9.2% and operating leverage despite higher compensation costs. Invigorate program delivering productivity improvements to offset inflationary pressures.
Watch Items from the Filing
- New Corewell Health venture closed January 2026: 51% Quest / 49% Corewell ownership of Michigan lab entity; contributed $38M cash and valued noncontrolling interest at $253M; accounted for ~7% of Q1 organic volume growth.
- Pending litigation: AMCA data security incident (2019) involving 2.2M customers' financial/medical data; discovery ongoing; company reserves $20M for legal matters but notes material loss cannot be estimated at this stage.
- Revenue concentration by payer: Healthcare insurers 36%, Government payers 16%, Client payers 32%, Patients 14%; limited single-customer concentration risk disclosed.
- Contingent consideration liability of $99M related primarily to Haystack Oncology acquisition; fair value increased $3M in Q1 2026; dependent on revenue benchmarks through 2028 and CMS reimbursement coverage.
- Invigorate restructuring program aims to deliver 3% annual cost savings; Q1 2026 restructuring charges of $7M (vs. $11M prior year) for workforce reductions; additional charges expected in future periods.
AI-extracted and verified against SEC EDGAR filing text. Not investment advice.
Revenue
Q1 2026
$2.9B
Net Income
Q1 2026
$252.0M
Free Cash Flow
Q1 2026
$164.0M
Operating Margin
Q1 2026
13.8%
ROIC
Q1 2026
3.2%
D/E Ratio
Q1 2026
0.77
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · Pro+Revenue
+11.8% YoYNet Income
+13.9% YoYOperating Income
+15.6% YoYEPS (Diluted)
+13.8% YoYTotal Assets
+0.4% YoYTotal Debt
-9.4% YoYOp. Cash Flow
+41.4% YoY| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $11.04B +11.8% | $9.87B +6.7% | $9.25B -6.4% | $9.88B -8.4% | $10.79B +14.3% | $9.44B |
| Net Income | $992.0M +13.9% | $871.0M +2.0% | $854.0M -9.7% | $946.0M -52.6% | $2.00B +39.4% | $1.43B |
| Operating Income | $1.56B +15.6% | $1.35B +6.7% | $1.26B -11.6% | $1.43B -40.0% | $2.38B +20.8% | $1.97B |
| EPS (Diluted) | $8.75 +13.8% | $7.69 +2.7% | $7.49 -6.0% | $7.97 -48.7% | $15.55 +48.5% | $10.47 |
| Total Assets | $16.23B +0.4% | $16.15B +15.2% | $14.02B +9.2% | $12.84B -5.7% | $13.61B -3.0% | $14.03B |
| Total Debt | $6.17B -9.4% | $6.82B +35.9% | $5.02B +26.0% | $3.98B -0.8% | $4.01B -0.1% | $4.02B |
| Operating Cash Flow | $1.89B +41.4% | $1.33B +4.9% | $1.27B -26.0% | $1.72B -23.1% | $2.23B +11.4% | $2.00B |
Get alerted when DGX's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for QUEST DIAGNOSTICS INC including:
Top Institutional Holders of DGX
BlackRock, Inc.
$1.8B9,172,292 shVANGUARD CAPITAL MANAGEMENT LLC
$1.4B7,145,672 shVANGUARD PORTFOLIO MANAGEMENT LLC
$1.2B6,081,400 shSTATE STREET CORP
$1.1B5,380,821 shBoston Partners
$786.7M4,012,232 shGEODE CAPITAL MANAGEMENT, LLC
$602.7M3,086,308 shMORGAN STANLEY
$486.0M2,479,720 shEdgePoint Investment Group Inc.
$439.8M2,243,869 shDIMENSIONAL FUND ADVISORS LP
$382.1M1,949,535 shGrantham, Mayo, Van Otterloo & Co. LLC
$369.0M1,883,024 sh
| Fund | Value | Shares |
|---|---|---|
| BlackRock, Inc. | $1.8B | 9,172,292 |
| VANGUARD CAPITAL MANAGEMENT LLC | $1.4B | 7,145,672 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $1.2B | 6,081,400 |
| STATE STREET CORP | $1.1B | 5,380,821 |
| Boston Partners | $786.7M | 4,012,232 |
| GEODE CAPITAL MANAGEMENT, LLC | $602.7M | 3,086,308 |
| MORGAN STANLEY | $486.0M | 2,479,720 |
| EdgePoint Investment Group Inc. | $439.8M | 2,243,869 |
| DIMENSIONAL FUND ADVISORS LP | $382.1M | 1,949,535 |
| Grantham, Mayo, Van Otterloo & Co. LLC | $369.0M | 1,883,024 |
More Healthcare Companies
View all Healthcare →Put DGX on your watchlist
Track score changes the day QUEST DIAGNOSTICS INC files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is DGX a good stock to buy?
13F Pro's AI-powered analysis of QUEST DIAGNOSTICS INC (DGX) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on NYSE). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for DGX are available on the DGX stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.
Which hedge funds own DGX?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling DGX. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of QUEST DIAGNOSTICS INC's investment landscape.